Approximately 19% of ICH patients in the INTERACT3 trial were ≤50 years old.
Younger patients had larger hematoma volumes but significantly lower 6-month mortality (9.1% vs 16.6%; adjusted OR 0.42) and reduced disability.
A significant age-by-treatment interaction suggested younger patients benefited more from the bundled care intervention.
Younger patients reported better quality of life across mobility, self-care, and usual activities.
Distinct risk profile: higher rates of smoking, alcohol use, male predominance, and higher BMI in younger group.
Study snapshot
